SAN DIEGO, Oct. 27 /PRNewswire/ -- SGX Pharmaceuticals today announced that Karin Eastham has been elected to the company’s board of directors. As a director, Ms. Eastham will also serve as chair of the audit committee.
Ms. Eastham has over 25 years experience in financial and operations management, primarily in life science and biotechnology companies. She currently serves as Executive Vice President and Chief Operating Officer and a member of the board of trustees of the Burnham Institute for Medical Research, positions she has held since May 2004. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President and Chief Financial Officer at Diversa Corporation. She previously held similar positions with CombiChem, Inc., Cytel Corporation, and Boehringer Mannheim Corporation.
Ms. Eastham serves as a director for Tercica, Inc., Illumina, Inc., Amylin Pharmaceuticals, Inc. and Cyntellect, Inc. She also serves on the Board of UCSD’s Athena program. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director.
About SGX Pharmaceuticals
SGX Pharmaceuticals (SGX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.
SGX Pharmaceuticals
CONTACT: Jason Spark of Atkins + Associates, +1-858-527-3491,jspark@irpr.com, for SGX Pharmaceuticals
